Portal de Periódicos da CAPES

Rules of Evidence:

2005; Wiley; Volume: 28; Issue: 2 Linguagem: Inglês

10.1111/j.1540-8159.2005.09575.x

1540-8159

Michael O. Sweeney, Mark H. Schoenfeld, David S. Cannom,

Cardiac Arrhythmias and Treatments

Pacing and Clinical ElectrophysiologyVolume 28, Issue 2 p. 81-88 Rules of Evidence: CMS and Primary Prevention of Sudden Cardiac Death in Systolic Heart Failure MICHAEL O. SWEENEY, MICHAEL O. SWEENEY Brigham and Women's Hospital, Boston, MassachusettsSearch for more papers by this authorMARK H. SCHOENFELD, MARK H. SCHOENFELD Hospital of Saint Raphael, New Haven, ConnecticutSearch for more papers by this authorDAVID S. CANNOM, DAVID S. CANNOM Good Samaritan Hospital, Los Angeles, CaliforniaSearch for more papers by this author MICHAEL O. SWEENEY, MICHAEL O. SWEENEY Brigham and Women's Hospital, Boston, MassachusettsSearch for more papers by this authorMARK H. SCHOENFELD, MARK H. SCHOENFELD Hospital of Saint Raphael, New Haven, ConnecticutSearch for more papers by this authorDAVID S. CANNOM, DAVID S. CANNOM Good Samaritan Hospital, Los Angeles, CaliforniaSearch for more papers by this author First published: 28 January 2005 https://doi.org/10.1111/j.1540-8159.2005.09575.xCitations: 12 Address for correspondence: Michael O. Sweeney, M.D., Cardiac Arrhythmia Service, Brigham and Women's Hospital, Boston, MA 02115. Fax: (617) 732-7596; e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Mirowski M, Mower MM, Staewen WS, et al. Standby automatic defibrillator. An approach to prevention of sudden coronary death. Arch Int Med 1970; 126: 158–161.DOI: 10.1001/archinte.126.1.158 2 Lown B, Axelrod PC. Implanted standby defibrillators (editorial). Circulation 1972; 46: 637–639. 3 Schoenfeld MH. Updating the guidelines for pacemaker/defibrillator device implantation: An historical perspective and a guide to their interpretation. J Cardiovasc Electrophysiol 2002; 13: 1200–1201.DOI: 10.1046/j.1540-8167.2002.01200.x 4 Cannom DS, Prystowsky EN. The evolution of the implantable cardioverter defibrillator. Pacing Clin Electrophysiol 2004; 27: 419–431. 5 The Antiarrhythmics Versus Implantable Defibrillator (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576–1583.DOI: 10.1056/NEJM199711273372202 6 Connolly SJ, Gent M, Roberts RS, et al. for the CIDS Investigators. Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297–1302. 7 Kuck KH, Cappato R, Siebels J, et al. for the CASH Investigators. Randomized comparison of antiarrhythmia drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748–754. 8 Moss AJ, Hall WJ, Cannom DS, et al. for the Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1993–1940. 9 Buxton AE, Lee KL, Fisher JD, et al. for the Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death among patients with coronary artery disease. N Engl J Med 1999; 341: 1882–1890. 10 Moss AJ, Zareba W, Hall WJ, et al, for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877–883.DOI: 10.1056/NEJMoa013474 11 Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidlines). Circulation 2002; 106: 2145–2161. 12 Gillum RF. Sudden coronary death in the United States. Circulation 1989; 79: 756–765. 13 Moss AJ. Sudden cardiac death and national health. Pacing Clin Electrophysiol 1993; 16: 2190–2191. 14 Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone vs. implantable defibrillator: Randomized trial in patients with nonischemic cardiomyopathy and asymptomatic nonsustained ventricular tachycardia—AMIOVIRT. J Am Coll Cardiol 2003; 41: 1707–1712.DOI: 10.1016/S0735-1097(03)00297-3 15 Bansch D, Antz M, Boczor S, et al. for the CAT Investigators. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: The Cardiomyopathy Trial (CAT). Circulation 2002; 105: 1453–1458. 16 Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 351: 2151–2158.DOI: 10.1056/NEJMoa033088 17 Cairns J, Connolly SJ, Roberts RS, et al. for the CAMIAT Investigators. Randomized trial of outcome after myocardial infarction among patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 1997; 349: 675–682. 18 Julian DG, Camm AJ, Frangin G, et al. for the EMIAT Investigators. Randomized trial of effect of amiodarone on mortality among patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667–674.DOI: 10.1016/S0140-6736(96)09145-3 19 Singh SN, Fletcher RD, Fisher SG, et al. for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. Amiodarone among patients with congestive heart failure and asymptomatic ventricular arrhythmias. N Engl J Med 1995; 333: 77–82.DOI: 10.1056/NEJM199507133330201 20 Zareba W, Moss AJ. Noninvasive risk stratification in post infarction patients with severe left ventricular dysfunction and methodology of the MADIT II noninvasive electrocardiology substudy. J Electrocardiol 2003; 36(Suppl): 101–108.DOI: 10.1016/j.jelectrocard.2003.09.022 21 Bristow MR, Feldman AM, Saxon LA, et al. for the COMPANION Investigators. COMPANION. In: Heart Failure Society of America Late Breaking Clinical Trial Presentation 2003. 22 Connolly SJ, Hohnloser SH. Defibrillator in Acute Myocardial Infarction Trial. In: American College of Cardiology 53rd Scientific Sessions Late Breaking Clinical Trials New Orleans , Louisiana 2004. 23 Curtis AB, Langberg JJ, Tracy CM. Clinical competency statement: Implantation and follow-up of cardioverter-defibrillators. J Cardiovasc Electrophysiol 2001; 12: 280–284. 24 Curtis AM, Ellenbogen KA, Hammill SC, et al. Clinical competency statement: Training pathways for implantation of cardioverter defibrillators and cardiac resynchronization devices. Heart Rhythm 2004; 1: 371–375. 25 Fisher JD, Mehra R, Furman S. Termination of ventricular tachycardia with bursts of rapid ventricular pacing. Am J Cardiol 1978; 41: 94–102.DOI: 10.1016/0002-9149(78)90138-8 26 Wathen MS, Sweeney MO, DeGroot P, et al. for the PainFREE Rx Investigators. Shock reduction using antitachycardia pacing for rapid spontaneous ventricular tachycardia in patients with coronary artery disease. Circulation 2001; 104: 796–801. 27 Wathen MS, DeGroot PJ, Sweeney MO, et al. for the PainFREE Rx II Investigators. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter defibrillators. PainFREE Rx II Trial Results. Circulation 2004; 110: 2592–2596. 28 Sweeney MO, Wathen MS, Abdalla I, et al. Primary and secondary prevention ICD patients have similar proportions of ventricular tachyarrhythmia detections and equivalent risk for spurious therapies: Results from PainFREE Rx II (Abstract). J Am Coll Cardiol 2004; 43: 125A.DOI: 10.1016/S0735-1097(04)90523-2 29 Sears SF, Conti JB. Understanding implantable cardioverter defibrillator shocks and storms: Medical and psychosocial considerations for research and clinical care. Clin Cardiol 2003; 26: 107–111. 30 Schron EB, Exner DV, Yao Q, et al. for the AVID Investigators. Quality of life in the antiarrhythmics versus implantable defibrillators trial. Impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002; 105: 589–594. 31 Namerow PB, Firth BR, Heywood GM, et al. for the CABG Patch Trial Investigators and Coordinators. Quality of life six months after CABG surgery in patients randomized to ICD versus no ICD therapy: Findings from the CABG Patch Trial. Pacing Clin Electrophysiol 1999; 22: 1305–1313. 32 Irvine J, Dorian P, Baker B, et al. for the CIDS Investigators. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J 2002; 144: 282–289. 33 Exner DV. Quality of life in patients with life threatening arrhythmias: Does choice of therapy make a difference? Am Heart J 2002; 144: 208–211.DOI: 10.1067/mhj.2002.124051 34 Wathen MS, Khaligi K, Voloson KJ, et al. for the PainFREE Rx II Investigators. Antitachycardia pacing of fast ventricular tachycardia improves quality of life in implantable cardiac defibrillator patients. Circulation 2003; 108: IV–615. 35 Bigger JT, for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med 1997; 337: 1569–1575. 36 Bardy GH, for the Sudden Cardiac Death in Heart Failure Trial Investigators (SCD-HeFT). The sudden cardiac death in heart failure trial (SCD-HeFT). In: American College of Cardiology , New Orleans , 2004. 37 Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Developed in Collaboration with the International Society for Heart and Lung Transplantation Endorsed by the Heart Failure Society of America. J Heart Lung Transplant 2002; 21: 189–203.DOI: 10.1016/S1053-2498(01)00776-8 38 The DAVID Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: The dual chamber and VVI implantable defibrillator (DAVID) trial. J Am Med Assoc 2002; 288: 3115–3123.DOI: 10.1001/jama.288.24.3115 39 Steinberg JS, Maniar P, Zareba W, et al. for the MADIT-II Investigators. The relationship between right ventricular pacing and outcomes in MADIT-II patients. In: North American Society of Pacing and Electrophysiology Annual Scientific Sessions , Washington , DC , 2003. 40 Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 2003; 23: 2932–2937. 41 Sharma AD, Rizo-Patron C, Hallstrom AP, et al. and the DAVID Investigators. Right ventricular pacing percent independently predicts outcomes in the DAVID trial. Circulation 2003; 108: IV–628. 42 Andersen HR, Nielsen JC, Rhomsen PEB, et al. Long-term follow-up of patients from a randomized trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet 1997; 350: 1210–1216.DOI: 10.1016/S0140-6736(97)03425-9 43 Gotzsche PC. Why we need a broad perspective on meta-analysis. Br Med J 2000; 321: 585–586. 44 Naccarelli J. Personal communication, November, 2004. 45 Ruskin JN, Camm AJ, Zipes DP, et al. Implantable cardioverter defibrillator utilization based on discharge diagnoses from Medicare and managed care patients. J Cardiovasc Electrophysiol 2002; 13: 38–43.DOI: 10.1046/j.1540-8167.2002.00038.x 46 Cannom DS, Prystowsky E. Management of ventricular arrhythmias—Detection, drugs, and devices. J Am Med Assoc 1999; 281(2): 172–179. 47 Fisher ES, Wennberg DE, Stukel TA, et al. The implications of regional variations in Medicare spending 2. Health outcomes and satisfaction with care. Ann Int Med 2003; 138: 288–298. 48 Redelmeier DA, Tversky A. Discrepancy between medical decisions for individual patients and for groups. N Engl J Med 1990; 322: 1162–1164. 49 Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2004; 348: 1866–1874.DOI: 10.1056/NEJMoa022147 Citing Literature Volume28, Issue2February 2005Pages 81-88 ReferencesRelatedInformation